Praluent Cost in Louisiana 2026: Price, Insurance, Medicaid, and Compounding Options

What Is Praluent and Why Does Cost Matter in Louisiana?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on hepatocyte surfaces, which dramatically lowers circulating LDL-C. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

Cost is the single largest barrier. Louisiana has one of the highest rates of cardiovascular disease mortality in the United States, with age-adjusted heart disease death rates consistently above the national average [2]. Patients who need a PCSK9 inhibitor and cannot afford $580 per month often go untreated, which carries direct mortality risk given what the clinical data show.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction explicitly recommends PCSK9 inhibitors for very-high-risk ASCVD patients whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe [3]. Louisiana prescribers and patients therefore need accurate, current information on every cost pathway available.

Current Praluent List Price in Louisiana (2026)

The manufacturer list price for Praluent in 2026 sits at approximately $580 per month, which covers a supply of two prefilled auto-injector pens (75 mg/mL or 150 mg/mL) dosed every two weeks [4]. That figure has remained relatively stable since Sanofi and Regeneron significantly reduced the list price from its original $14,600-per-year launch price in 2019 following payer pressure and competition from evolocumab (Repatha).

Cash-pay patients at Louisiana retail pharmacies, including Walgreens, CVS, and Kroger locations in Baton Rouge and New Orleans, typically see prices at or near the $580 list price without a discount program. GoodRx and similar discount platforms may bring that figure down modestly, though the range seen across Louisiana ZIP codes in early 2026 stays close to list for this particular biologic [5].

Two doses are standard: the 75 mg every-two-weeks starting dose, with uptitration to 150 mg every two weeks if LDL-C response is inadequate at week 8 [1]. Some patients qualify for monthly 300 mg dosing (two 150 mg injections given on the same day), which does not change the per-month supply cost at most pharmacies.

Patients paying full cash price for 12 months face an annual out-of-pocket burden near $6,960. That figure places Praluent out of reach for a substantial portion of Louisiana households; the state's median household income was approximately $54 to 000 in the most recent Census estimates [6].

Louisiana Medicaid Coverage for Praluent

Louisiana Medicaid does not cover Praluent (alirocumab) for the overwhelming majority of enrollees as of 2026 [7]. The Louisiana Department of Health Pharmaceutical and Therapeutics Committee has historically required demonstration of failure on multiple statin and ezetimibe regimens, along with confirmed genetic testing for HeFH, as preconditions for PCSK9 inhibitor consideration, and even then coverage has not been consistently granted on the standard Louisiana Medicaid fee-for-service formulary.

This coverage gap is clinically significant. A 2020 analysis in JAMA Cardiology found that Medicaid patients with ASCVD were substantially less likely to receive PCSK9 inhibitor therapy than commercially insured counterparts, a disparity that correlates with worse cardiovascular outcomes in lower-income populations [8]. Louisiana Medicaid managed care organizations (Aetna Better Health of Louisiana, Healthy Blue, Louisiana Healthcare Connections, AmeriHealth Caritas) each maintain separate formularies. Patients enrolled in one of these MCOs should request a specific formulary review and, if clinically indicated, pursue a prior authorization appeal with documentation of statin intolerance and LDL-C levels above guideline thresholds.

The ACC/AHA 2022 guideline states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C level is 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add a PCSK9 inhibitor to further reduce LDL-C" [3]. Submitting that guideline language alongside documented LDL-C values strengthens a prior authorization request regardless of insurer.

Commercial Insurance Coverage in Louisiana

Coverage for Praluent across commercial plans in Louisiana depends almost entirely on the individual plan's specialty tier structure and prior authorization criteria. Most Blue Cross and Blue Shield of Louisiana, Humana, and UnitedHealthcare commercial plans place alirocumab on a specialty tier with a required prior authorization [9].

Typical prior authorization criteria across major Louisiana commercial insurers in 2026 include: confirmed diagnosis of HeFH or established ASCVD, documented LDL-C of 70 mg/dL or higher despite at least 90 days of maximally tolerated statin therapy, and documented trial of ezetimibe. Some plans also require bempedoic acid (Nexletol) failure before approving a PCSK9 inhibitor [10].

Once approved, specialty tier cost-sharing often runs $100 to $300 per month depending on the plan's out-of-pocket structure. The Regeneron/Sanofi savings card (discussed below) can reduce that cost-share to near zero for eligible commercially insured patients.

Louisiana employers with self-funded ERISA plans can adopt their own formulary decisions independent of state insurance mandates, so coverage determinations vary. Patients with self-funded employer plans should contact their plan's pharmacy benefit manager (PBM) directly.

The Regeneron/Sanofi Praluent Savings Card

Regeneron and Sanofi jointly operate a co-pay assistance program for commercially insured patients that can reduce monthly out-of-pocket cost to as little as $0 per month for eligible participants [11]. The program is not available to patients whose primary coverage is a federal or state government program, including Medicare Part D and Louisiana Medicaid, under federal anti-kickback regulations.

Eligible patients enroll through the Praluent.com patient savings portal or by calling 1-844-PRALUENT. The savings card works at participating retail and specialty pharmacies across Louisiana. The maximum annual benefit under the program has historically been capped (specific annual maximums may change; patients should verify current terms directly with Regeneron/Sanofi at enrollment) [11].

Patients approaching the annual cap mid-year have two main options: request a bridge supply through a patient assistance program (described below), or discuss dose optimization with their prescriber to determine whether LDL-C goals can be maintained on the 75 mg dose rather than 150 mg.

Patient Assistance Program (PAP) for Uninsured Louisiana Patients

Sanofi offers the Sanofi Patient Assistance Program (Sanofi PAP) for uninsured or underinsured patients who meet income eligibility criteria, generally at or below 600% of the federal poverty level [12]. Approved patients receive Praluent at no cost shipped directly to their home or prescriber's office.

Louisiana patients can apply online through the Sanofi Cares North America portal or request a paper application through their prescriber. Approval typically takes two to four weeks and requires proof of income, a completed prescriber attestation, and documentation of lack of insurance coverage. The program renews annually.

For patients who do not qualify for Sanofi PAP but cannot afford retail pricing, NeedyMeds and RxAssist maintain searchable databases of manufacturer PAP programs and include Sanofi Praluent entries updated quarterly [5].

Compounded Alirocumab in Louisiana: Legal Status and Cost

Compounded alirocumab prepared by a state-licensed 503A compounding pharmacy is legal in Louisiana as of 2026, provided the pharmacy is licensed by the Louisiana Board of Pharmacy and the compound is prepared pursuant to a valid patient-specific prescription from a licensed Louisiana prescriber [13]. The 503A designation refers to traditional patient-specific compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows licensed pharmacists to compound drugs not commercially available or when a patient has a documented clinical need that cannot be met by the FDA-approved product [14].

The critical legal distinction is that 503A pharmacies compound for individual patients. They do not manufacture large batches for office use or general sale. A Louisiana prescriber writing a prescription for compounded alirocumab must document a legitimate clinical rationale; cost alone may not satisfy some pharmacies' internal compliance requirements, though many do accept cost-related medical necessity as sufficient.

Cost for compounded alirocumab through Louisiana-licensed 503A pharmacies varies by formulation and pharmacy. Some HealthRX-affiliated compound pharmacy partners list compounded alirocumab at near-zero cost for qualifying patients depending on their specific programs. Patients should obtain a written quote including all dispensing and shipping fees before committing.

The FDA has not placed alirocumab on its 503A Difficult-to-Compound list or its Demonstrably Copies list as of the article's publication date, meaning 503A compounding of alirocumab currently faces no specific federal prohibition beyond the standard requirements [14]. Patients and prescribers should verify current FDA guidance before initiating, as regulatory status of compounded biologics continues to evolve.

Compounding a monoclonal antibody is technically more complex than compounding a small-molecule drug. Patients choosing this route should confirm the pharmacy holds appropriate accreditation (PCAB accreditation from the Pharmacy Compounding Accreditation Board is the recognized national standard) and can provide certificates of analysis for each batch [13].

Telehealth Prescribing of Praluent in Louisiana

Telehealth prescribing of Praluent is legal in Louisiana in 2026. Louisiana lifted its pre-pandemic requirement for an initial in-person visit before a prescriber could initiate a new non-controlled prescription via telehealth, and that flexibility has been preserved in state statute [15]. A Louisiana-licensed physician, nurse practitioner, or physician assistant practicing under appropriate supervision agreements can evaluate a patient via synchronous audio-video telehealth, review labs, and write a valid Praluent prescription.

Patients pursuing the telehealth route should have recent lipid panel results available (within 90 days is typical for prior authorization purposes), a list of current statin and ezetimibe regimens with documented tolerability, and their insurance card information. The prescriber will typically send the prescription electronically to either the patient's preferred specialty pharmacy or to Praluent's dedicated specialty pharmacy network, which includes Accredo and CVS Specialty.

HealthRX clinicians licensed in Louisiana can evaluate alirocumab candidacy via telehealth. Patients with LDL-C persistently above 70 mg/dL on maximally tolerated statin therapy and confirmed ASCVD or HeFH are the most appropriate candidates under current ACC/AHA thresholds [3].

Clinical Evidence Supporting Alirocumab Use

The clinical case for alirocumab rests on a well-characterized body of evidence. The ODYSSEY OUTCOMES trial (N=18,924 patients with recent acute coronary syndrome randomized to alirocumab 75 mg/150 mg every two weeks vs. placebo, followed for a median of 2.8 years) published in the New England Journal of Medicine in 2018 demonstrated a 15% reduction in the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [16]. Absolute risk reduction was 1.6 percentage points (9.5% alirocumab vs. 11.1% placebo). The trial also found a pre-specified all-cause mortality reduction of 0.6 percentage points in the subgroup with baseline LDL-C at or above 100 mg/dL.

Mean LDL-C reduction from baseline was 54.7% at 48 weeks in the alirocumab arm vs. 0.8% in the placebo arm of ODYSSEY OUTCOMES [16]. That magnitude of reduction is consistent with earlier Phase 3 data from the ODYSSEY LONG TERM trial (N=2,341), which showed a 62% LDL-C reduction vs. placebo over 78 weeks [17].

The ACC/AHA Cholesterol Guideline (2018, updated 2022) assigns a Class IIa recommendation (Level of Evidence: A) to adding a PCSK9 inhibitor in very-high-risk ASCVD patients with LDL-C remaining at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [3]. The guideline text specifies: "A PCSK9 inhibitor may be considered for patients with very-high-risk ASCVD if the LDL-C level is 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy."

Familial hypercholesterolemia patients represent a separate, high-priority group. An estimated 1 in 250 individuals carries a heterozygous FH variant, and the CDC has designated FH a Tier 1 genomic condition given the availability of effective intervention [18]. In the ODYSSEY FH I and FH II trials (combined N=735), alirocumab reduced LDL-C by approximately 49% vs. placebo at week 24 [19].

Injection-site reactions occur in about 7% of alirocumab-treated patients vs. 5% of placebo patients in pooled Phase 3 data [1]. Neurocognitive adverse events were evaluated in the ODYSSEY OUTCOMES pre-specified analysis and did not differ significantly between alirocumab and placebo arms [16].

How Alirocumab Compares to Evolocumab (Repatha) on Cost in Louisiana

Louisiana patients often ask whether switching to evolocumab (Repatha, made by Amgen) would save money. Both drugs share a similar mechanism, similar efficacy in LDL-C lowering, and similar list prices. Repatha's list price in 2026 is approximately $585 per month, essentially indistinguishable from Praluent's $580 [4]. The Amgen ICER affordability threshold analysis from 2021 placed both PCSK9 inhibitors within comparable cost-effectiveness ranges at their post-reduction list prices [20].

Formulary placement, however, differs by payer. Some Louisiana commercial plans prefer one agent over the other on their specialty formulary. Patients whose prior authorization for Praluent is denied should ask their prescriber to check whether the same insurer has a more favorable tier placement for Repatha. Switching between two agents in the same drug class for formulary reasons is clinically straightforward; the prescriber simply adjusts the dosing equivalency.

Practical Cost-Reduction Decision Framework for Louisiana Praluent Patients

Patients and prescribers in Louisiana can work through the following sequence to find the lowest cost pathway:

Step 1: Determine insurance status. Commercial insurance with specialty coverage, Louisiana Medicaid, Medicare Part D, or uninsured each open a different primary pathway.

Step 2: Commercial insurance patients should first activate the Regeneron/Sanofi savings card, which may reduce cost-share to $0/month. If prior authorization is denied, file an appeal using ODYSSEY OUTCOMES data and ACC/AHA guideline language citing LDL-C threshold and risk category [3][16].

Step 3: Louisiana Medicaid patients face no current formulary coverage. Options include: (a) appeal through the MCO with documented HeFH genetic confirmation and statin failure; (b) contact the Sanofi PAP if income-eligible; (c) discuss compounded alirocumab via a licensed Louisiana 503A pharmacy with their prescriber.

Step 4: Uninsured patients should apply to Sanofi PAP first. If ineligible by income, compounded alirocumab via a licensed 503A pharmacy is the most accessible lower-cost route.

Step 5: Medicare Part D patients face the coverage gap dynamic under the redesigned Medicare Part D structure effective 2025, which caps out-of-pocket at $2,000 annually for covered Part D drugs [21]. If Praluent is covered on the plan's formulary, total annual cost-share should not exceed $2,000. Patients whose plan does not cover Praluent should file a formulary exception citing the clinical necessity standard.

A patient's prescriber must be involved at each step; prior authorization appeals and 503A compounding prescriptions require a licensed prescriber's active participation.

Dosing Reference for Louisiana Prescribers

The FDA-approved dosing for alirocumab is as follows per the prescribing information [1]:

Starting dose for most HeFH and ASCVD patients: 75 mg subcutaneous injection every two weeks. If LDL-C response is inadequate at week 8, dose may be uptitrated to 150 mg every two weeks. A 300 mg every-four-weeks (monthly) regimen is an alternative for patients who prefer less frequent administration; two 150 mg injections are given consecutively at the same visit or same home-administration session.

Patients self-administer using the single-dose prefilled auto-injector or prefilled syringe. Injection sites are the abdomen, thigh, or upper arm; sites should be rotated and injections should not be given into areas that are tender, bruised, or scarred [1].

No dose adjustment is required for mild or moderate renal impairment. Data on severe renal impairment are limited; use with caution and monitor LDL-C response at week 4 to 8 [1]. No dose adjustment is required for mild hepatic impairment. Praluent has not been studied in severe hepatic impairment and should be used with caution in that population [1].

Monitoring: fasting lipid panel at 4 to 8 weeks after initiation or dose change, then every 3 to 12 months based on clinical response and payer prior authorization renewal requirements [3].